AVXL News and Press, Anavex Life Sciences Corp.

2024-06-23 11:32:35 ET Summary Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trad...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...

2024-06-17 17:58:14 ET Summary An FDA advisory committee voted 11-0 in favor of Eli Lilly and Company's donanemab for the treatment of early Alzheimer's disease. Donanemab has no effect on non-APOE4 carriers, may slow the decline of APOE4 carriers closer to that of non-carriers, a...

2024-06-08 14:00:00 ET More on Eli Lilly, Biogen Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Biogen favored at RBC as Eli Lilly awaits FDA AdCom on Alzheimer’s drug FDA suggests safety warning for Eli Lilly Alzheimer’s drug ...

2024-05-22 16:11:06 ET Summary Anavex Life Sciences is a clinical-stage biopharmaceutical company developing innovative treatments for neurodegenerative diseases. Its leading drug candidate, Anavex 2-73 (Blarcamesine), targets the Sigma-1 and muscarinic receptors in the brain to e...

2024-05-22 11:15:20 ET More on Anavex Life Sciences Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Anavex Life Sciences Historical earnings data for Anavex Life Sciences Financial information for Anav...

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...

2024-05-19 01:10:48 ET Summary Anti-inflammatory drugs are likely to have limited effects on Alzheimer's disease because they are not stopping early oxidation and nitration. Neuroinflammation in Alzheimer's disease is primarily caused by oxidative and nitrosative stress. Inhib...

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares. Investors, who purchased Anavex Life Sciences Corp. (NASDAQ: AVXL) shares prior to Februa...

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsych...